Open access
Jul 2026
Isorhamnetin ameliorates active ulcerative colitis potentially involving the Nrf2-PTGS2 axis: an integrative study from clinical evidence mining to in vivo validation.
The key active component Iso shows therapeutic effects, with mechanisms potentially involving the Nrf2-PTGS2 axis and immune-inflammatory pathways and mechanisms potentially involving the Nrf2-PTGS2 axis and immune-inflammatory pathways.
Zhen-Jia Fan, Lu-Qing Zhao, Ning Ding et al.
· Naunyn-Schmiedeberg's Archiv... · 0 citations